Flash Finance

Abbott India LimitedABBOTINDIACorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹26,170.00
MCap ₹55,609 Cr · P/E 34.4
Abbott India Limited — Stock analysis & AI research Abbott India Limited — Seasonality — best & worst months Abbott India Limited — Technical indicators & charts Abbott India Limited — Technical setup — score, trend, support & resistance Abbott India Limited — Rectangle / Trading Range pattern forming Abbott India Limited — Live exchange announcements
📋 High ROE Stocks📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Low Debt Stocks📋 High Promoter Holding Stocks 📈 Multi-Timeframe Bearish Stocks📈 Stocks Near 52-Week Low ⚖️ vs GlaxoSmithKline Pharmaceuticals⚖️ vs Pfizer 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹1,814 Cr
Sales · Jun 2026
+4.4% YoY
₹522 Cr
Operating Profit · Jun 2026
+17.0% YoY
28.8%
OPM % · Jun 2026
+12.1% YoY
₹429 Cr
Net Profit · Jun 2026
+17.2% YoY
₹201.66
EPS · Jun 2026
+17.1% YoY

📝 Abbott India Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Abbott India Limited reported revenue of ₹1,814 crore for the quarter ended June 2026 (Q1 FY27), up 4.4% from ₹1,738 crore in the same quarter last year, and up 6.1% sequentially over the March 2026 quarter.

Net profit rose 17.2% year-on-year to ₹429 crore, from ₹366 crore. Earnings per share (EPS) came in at ₹201.66.

Operating profit stood at ₹522 crore — an operating margin (OPM) of 28.8%, compared with 25.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Abbott India Limited posted revenue of ₹6,929 crore, a growth of 8.1% over FY25, with a net profit of ₹1,552 crore (up 9.7% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹7,005 crore with a net profit of ₹1,615 crore.

Valuation snapshot

At the current price of ₹26,170.00, ABBOTINDIA has a market capitalisation of ₹55,609 crore and a trailing P/E of about 34.4.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 13th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 74.99%, foreign institutional investors (FIIs) 0.27%, domestic institutional investors (DIIs) 8.93%, public shareholders 15.81% of Abbott India Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹55,609 Cr
Current Price ?
₹26,170.0
P/E ?
34.43below ind
Industry P/E ?
35.00
P/B ?
11.65
P/S ?
7.94
P/FCF ?
42.55
Enterprise Value ?
₹55,781 Cr
EV/EBITDA ?
28.34
PEG ?
1.91
Earnings Yield ?
3.4%
Dividend Yield ?
2.00%
Profitability & Returns
Sales (TTM) ?
₹7,005 Cr
OPM ?
28.1%
Profit after tax (TTM) ?
₹1,615 Cr
EPS (TTM) ?
₹760.13
ROCE ?
45.0%
ROE ?
33.8%
ROA ?
24.8%
Growth
Sales — latest qtr ?
₹1,814 Cr
PAT — latest qtr ?
₹429 Cr
YoY qtr sales growth ?
4.4%
YoY qtr profit growth ?
17.2%
Sales growth (3y) ?
9%
Sales growth (5y) ?
10%
Profit growth (3y) ?
18%
Profit growth (5y) ?
18%
Financial Health
Debt ?
₹172 Cr
Debt to Equity ?
0.04
Interest Coverage ?
72.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
74.99%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-6.7%
Return 6 months ?
1.5%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1,3431,4791,4941,4371,4391,5581,6331,6141,6051,7381,7571,7241,7101,814 +4.4% +6.1%
Operating Profit 280355381388330391439436429446502463481522 +17.0% +8.5%
Other Income 5056565681676072767370707675 +2.7% -1.3%
Interest 43333322468566 +0.0% +0.0%
Depreciation 1717181818181818181919191920 +5.3% +5.3%
Profit Before Tax 308390415422390437479488483493546509531572 +16.0% +7.7%
Net Profit 231290313311287328359361367366415376395429 +17.2% +8.6%
EPS 108.91136.59147.27146.35135.09154.36168.76169.78172.72172.18195.42176.92185.86201.66 +17.1% +8.5%
OPM % 20.8% 24.0% 25.5% 27.0% 22.9% 25.1% 26.9% 27.0% 26.7% 25.7% 28.6% 26.9% 28.1% 28.8% +12.1% +2.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹6,410 Cr ₹6,929 Cr ₹7,005 Cr +8.1%
Operating Profit ₹1,695 Cr ₹1,893 Cr ₹1,969 Cr +11.7%
OPM % 26.44% 27.31% 28.10% +3.3%
NPM % 22.08% 22.40% 23.06% +1.4%
Other Income ₹275 Cr ₹289 Cr ₹291 Cr +5.0%
Depreciation ₹72 Cr ₹75 Cr ₹76 Cr +4.8%
Interest ₹11 Cr ₹25 Cr ₹25 Cr +129.2%
EBIT ₹1,623 Cr ₹1,817 Cr ₹1,892 Cr +12.0%
PBT ₹1,887 Cr ₹2,079 Cr ₹2,158 Cr +10.2%
Tax ₹116 Cr ₹264 Cr ₹264 Cr +128.0%
Net Profit ₹1,415 Cr ₹1,552 Cr ₹1,615 Cr +9.7%
EPS ₹665.62 ₹730.38 ₹759.86 +9.7%
Material Cost ₹974 Cr ₹1,796 Cr ₹1,796 Cr +84.4%
Employee Cost ₹144 Cr ₹355 Cr ₹355 Cr +145.9%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 21212121 +0.0%
Reserves 3,1673,6784,2124,753 +12.8%
Borrowings 11383197172 -12.7%
Other Liabilities 1,2541,4111,4871,556 +4.6%
Total Liabilities 4,5565,1935,9176,502 +9.9%
Fixed Assets 237225336331 -1.5%
CWIP 410186 -66.7%
Investments 0000 —
Other Assets 4,3154,9585,5636,165 +10.8%
Total Assets 4,5565,1935,9176,502 +9.9%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 8931,2131,0121,319 +30.3%
Cash from Investing Activity -148-416182-371 -303.8%
Cash from Financing Activity -639-745-925-1,066 -15.2%
Net Cash Flow 10752269-118 -143.9%
Free Cash Flow 8601,1659601,307 +36.1%
CFO/OP 102%111%86%98% +14.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 22202219 -13.6%
Inventory Days 80709294 +2.2%
Days Payable 109114110109 -0.9%
Cash Conversion Cycle -8-2433 +0.0%
Working Capital Days -8-14972 -97.9%
ROCE % 41%46%46%45% -2.2%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 74.99%74.99%74.99%74.99% +0.0%
FIIs 0.16%0.16%0.19%0.27% +42.1%
DIIs 9.18%9.11%9.00%8.93% -0.8%
Public 15.67%15.74%15.83%15.81% -0.1%
No. of Shareholders 67,58471,19975,80175,866 +0.1%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Abbott India Limited's revenue in Q1 FY27?
Abbott India Limited reported revenue of ₹1,814 crore for the quarter ended June 2026 (Q1 FY27), up 4.4% from ₹1,738 crore in the same quarter last year, and up 6.1% sequentially over the March 2026 quarter.
What was Abbott India Limited's net profit in Q1 FY27?
Net profit rose 17.2% year-on-year to ₹429 crore, from ₹366 crore. Earnings per share (EPS) came in at ₹201.66.
What is ABBOTINDIA's market capitalisation and P/E ratio?
At the current price of ₹26,170.00, ABBOTINDIA has a market capitalisation of ₹55,609 crore and a trailing P/E of about 34.4.
Who owns Abbott India Limited? (shareholding pattern)
As of Mar 2026, promoters held 74.99%, foreign institutional investors (FIIs) 0.27%, domestic institutional investors (DIIs) 8.93%, public shareholders 15.81% of Abbott India Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI